The Centers for Disease Control and Prevention loosened its COVID-19 guidelines, yet another acknowledgement that the virus is here to stay. The changes move the responsibility for risk reduction from institutions to individuals. (The New York Times)

Merck reported that its blockbuster diabetes drug Januvia may contain traces of carcinogen. The Food and Drug Administration advised that people taking Januvia should not stop using it without first talking to their healthcare provider. (U.S. News & World Report)

Novartis has reported the death of two children who were treated with its Zolgensma gene therapy. The children died of acute liver failure approximately six weeks after the one-time therapy was infused in Russia and Kazakhstan. (STAT)

Johnson & Johnson will end sales of its talc-based baby powder in 2023. The company has faced roughly 38,000 lawsuits from consumers claiming the talc products caused cancer due to contamination with asbestos. (Reuters)

The Food and Drug Administration is recommending that individuals exposed to COVID-19 take three at-home COVID tests. The agency initially advised taking two rapid antigen tests over a few days to rule out infection, but new studies suggest that the more limited testing protocol misses too many infections. (AP)